G1 Therapeutics Inc's Customers Performance

Name: G1 Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

GTHX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


GTHX's Source of Revenues		During the corresponding time, G1 Therapeutics Inc saw a revenue deteriorated by -60.97 % year on year, sequentially revenue grew by 14.3 %. While revenue at the G1 Therapeutics Inc 's corporate clients • List of GTHX Customers

for the same period G1 Therapeutics Inc revnue deteriorated by -60.97 % year on year, sequentially revenue grew by 14.3 %.

• List of GTHX Customers

G1 Therapeutics Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

G1 Therapeutics Inc's Comment on Sales, Marketing and Customers

The company provides COSELA to qualifying uninsured or underinsured patients through a third-party service provider. Less than 3% of utilization occurs via this patient support program. Its customers include third-party payors and patients covered by federal healthcare programs such as Medicare and Medicaid. The company's marketing, sales, and distribution activities are subject to healthcare laws and regulations, including the federal Anti-Kickback Statute, false claims laws, and HIPAA.

News about G1 Therapeutics Inc Contracts

Trilaciclib: Paving the Way for Improved Survival Outcomes in Metastatic Triple Negative Breast Cancer

In a world where advancements in medical research are constantly underway, the fight against breast cancer has seen significant breakthroughs. Recently, G1 Therapeutics presented groundbreaking data at the 2023 San Antonio Breast Cancer Symposium (SABCS) that shed light on the long-term impact of trilaciclib on survival outcomes in patients with metastatic Triple Negative Breast Cancer (TNBC). With TNBC known for its aggressive nature and limited treatment options, these findings have the potential to revolutionize the lives of cancer patients worldwide.
Understanding Triple Negative Breast Cancer:
Triple Negative Breast Cancer represents approximately 15-20% of all breast cancer cases and ...

G1 Therapeutics Inc’s Comment on Sales, Marketing and Customers

GTHX's Stock Performance relative to it's Customers

GTHX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
G1 Therapeutics Inc	375.20	58.20	-44.77	55
SUBTOTAL	0.00	0.00	0.00	-

Sources: G1 Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: G1 Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on G1 Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.